Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single Center, Single Arm Study to Evaluate the Decrease in CIPN With the Addition of Hydroxychloroquine to Chemotherapy in Patients With Early Stage (1-3) Breast Cancer and Gynecological Cancers Treated With Curative Intent

NCT05689359 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT05689359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05689359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single Center, Single Arm Study to Evaluate the Decrease in CIPN With the Addition of Hydroxychloroquine to Chemotherapy in Patients With Early Stage (1-3) Breast Cancer and Gynecological Cancers Treated With Curative Intent
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2024
Completion date
December 1, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chemotherapy-induced peripheral neuropathy, early-stage breast cancer, gynecologic cancer, peripheral neuropathy